PPP2R2D

Summary

PPP2R2D (protein phosphatase 2 regulatory subunit Bdelta, HGNC:23732) is a protein-coding gene on chromosome 10q26.3, encoding Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B delta isoform (Q66LE6). Substrate-recognition subunit of protein phosphatase 2A (PP2A) that plays a key role in cell cycle by controlling mitosis entry and exit.

Predicted to enable enzyme-substrate adaptor activity and protein phosphatase regulator activity. Predicted to be involved in exit from mitosis and regulation of chromosome segregation. Predicted to be located in cytoplasm. Predicted to be part of protein phosphatase type 2A complex. Predicted to be active in cytosol.

Source: NCBI Gene 55844 — RefSeq curated summary.

At a glance

• GWAS associations: 8
• Clinical variants (ClinVar): 5 total — 1 pathogenic
• MANE Select transcript: NM_018461

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:23732
Approved symbol	PPP2R2D
Name	protein phosphatase 2 regulatory subunit Bdelta
Location	10q26.3
Locus type	gene with protein product
Status	Approved
Aliases	MDS026, B55delta, B55D
Ensembl gene	ENSG00000175470
Ensembl biotype	protein_coding
OMIM	613992
Entrez	55844

Gene structure

Transcript identifiers

Ensembl transcripts: 14 — 7 protein_coding, 4 nonsense_mediated_decay, 3 retained_intron

ENST00000455566, ENST00000470416, ENST00000472664, ENST00000482010, ENST00000490777, ENST00000517472, ENST00000616467, ENST00000649083, ENST00000899910, ENST00000899911, ENST00000936866, ENST00000941365, ENST00000941366, ENST00000941367

RefSeq mRNA: 2 — MANE Select: NM_018461 NM_001291310, NM_018461

CCDS: CCDS73224

Canonical transcript exons

ENST00000455566 — 9 exons

Exon	Start	End
ENSE00001654980	131955684	131959834
ENSE00003562626	131945295	131945459
ENSE00003570760	131940582	131940694
ENSE00003579592	131943968	131944145
ENSE00003670526	131940031	131940196
ENSE00003673467	131947530	131947791
ENSE00003741791	131901238	131901330
ENSE00003753511	131901008	131901155
ENSE00003754496	131934458	131934555

Expression profiles

Bgee: expression breadth ubiquitous, 251 present calls, max score 96.02.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 11.5306 / max 118.9985, expressed in 1798 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
206060	5.1513	1701
206059	3.6689	1669
206061	2.1566	1159
206058	0.5537	293

Top tissues by expression

275 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
body of pancreas	UBERON:0001150	96.02	gold quality
adrenal tissue	UBERON:0018303	93.13	gold quality
left ovary	UBERON:0002119	93.05	gold quality
hindlimb stylopod muscle	UBERON:0004252	92.70	gold quality
cerebellar hemisphere	UBERON:0002245	92.50	gold quality
right adrenal gland cortex	UBERON:0035827	92.46	gold quality
cerebellar cortex	UBERON:0002129	92.44	gold quality
right hemisphere of cerebellum	UBERON:0014890	92.32	gold quality
right adrenal gland	UBERON:0001233	92.29	gold quality
pancreas	UBERON:0001264	92.25	gold quality
cortical plate	UBERON:0005343	92.00	gold quality
left adrenal gland	UBERON:0001234	91.93	gold quality
cerebellum	UBERON:0002037	91.88	gold quality
ganglionic eminence	UBERON:0004023	91.87	gold quality
primary visual cortex	UBERON:0002436	91.75	gold quality
left adrenal gland cortex	UBERON:0035825	91.75	gold quality
adenohypophysis	UBERON:0002196	91.74	gold quality
right ovary	UBERON:0002118	91.66	gold quality
pituitary gland	UBERON:0000007	91.62	gold quality
adrenal cortex	UBERON:0001235	91.43	gold quality
adrenal gland	UBERON:0002369	91.42	gold quality
apex of heart	UBERON:0002098	91.34	gold quality
prefrontal cortex	UBERON:0000451	90.89	gold quality
calcaneal tendon	UBERON:0003701	90.88	gold quality
granulocyte	CL:0000094	90.73	gold quality
Brodmann (1909) area 23	UBERON:0013554	90.68	gold quality
gastrocnemius	UBERON:0001388	90.65	gold quality
right atrium auricular region	UBERON:0006631	90.60	gold quality
lower esophagus muscularis layer	UBERON:0035833	90.46	gold quality
lower esophagus	UBERON:0013473	90.45	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.94

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): E2F1, NF1

miRNA regulators (miRDB)

80 targeting PPP2R2D, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6798-5P	100.00	65.77	699
HSA-MIR-4476	100.00	68.18	2030
HSA-MIR-6876-5P	100.00	67.68	2126
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-6870-5P	99.99	68.55	2115
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-3617-3P	99.98	67.86	918
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-4723-5P	99.97	68.70	2034
HSA-MIR-5698	99.97	68.49	2029
HSA-MIR-7111-5P	99.97	68.48	2062
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-128-3P	99.95	71.17	2484
HSA-MIR-216A-3P	99.95	71.19	2505
HSA-MIR-4525	99.94	64.38	675
HSA-MIR-5010-5P	99.94	64.11	705
HSA-MIR-144-3P	99.94	73.98	2698
HSA-MIR-329-3P	99.91	66.56	1234
HSA-MIR-362-3P	99.91	66.38	1267
HSA-MIR-6809-3P	99.91	71.45	3814
HSA-MIR-4493	99.90	66.48	977
HSA-MIR-3681-3P	99.88	70.46	2254
HSA-MIR-3065-3P	99.87	70.25	1407
HSA-MIR-383-3P	99.85	65.84	1359
HSA-MIR-205-5P	99.81	70.05	1557
HSA-MIR-6794-5P	99.76	66.38	1048
HSA-MIR-1208	99.70	68.28	1533
HSA-MIR-4716-3P	99.69	66.73	1022

Literature-anchored findings (GeneRIF, showing 6)

• These highly related members of the same subfamily of PP2A regulatory subunits differentially regulate TGF-beta/Activin/Nodal signalling to elicit opposing biological outcomes. (PMID:18697906)
• The -462 G>A variant of PPP2R2D affects NF1 binding to the proximal promoter of PPP2R2D. (PMID:22539979)
• The PP2A regulatory subunit PPP2R2D inhibits T-cell proliferation and survival within tumors. (PMID:24596207)
• Results show that PPP2R2D expression was significantly upregulated at the mRNA and protein levels in gastric cancer (GC) tissues and correlated with poor prognosis. Further evidence demonstrates an oncogenic role of PPP2R2D in GC progression and development through regulation of mTOR. (PMID:29568966)
• PPP2R2D suppresses IL-2 production and Treg function. (PMID:32897879)
• MicroRNA-5010-5p ameliorates high-glucose induced inflammation in renal tubular epithelial cells by modulating the expression of PPP2R2D. (PMID:38442987)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	ppp2r2d	ENSDARG00000102009
mus_musculus	Ppp2r2d	ENSMUSG00000041769
rattus_norvegicus	Ppp2r2d	ENSRNOG00000016940
caenorhabditis_elegans	sur-6	WBGENE00006352

Paralogs (3): PPP2R2C (ENSG00000074211), PPP2R2B (ENSG00000156475), PPP2R2A (ENSG00000221914)

Protein

Protein identifiers

Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B delta isoform — Q66LE6 (reviewed: Q66LE6)

Alternative names: PP2A subunit B isoform B55-delta, PP2A subunit B isoform PR55-delta, PP2A subunit B isoform R2-delta, PP2A subunit B isoform delta

All UniProt accessions (5): A0A096LPI9, A0A0A6YYD6, A0A3B3IRK1, Q66LE6, H0YB06

UniProt curated annotations — full annotation on UniProt →

Function. Substrate-recognition subunit of protein phosphatase 2A (PP2A) that plays a key role in cell cycle by controlling mitosis entry and exit. Involved in chromosome clustering during late mitosis by mediating dephosphorylation of MKI67. The activity of PP2A complexes containing PPP2R2D (PR55-delta) fluctuate during the cell cycle: the activity is high in interphase and low in mitosis.

Subunit / interactions. PP2A consists of a common heterodimeric core enzyme, composed of a 36 kDa catalytic subunit (subunit C) and a 65 kDa constant regulatory subunit (PR65 or subunit A), that associates with a variety of regulatory subunits. Proteins that associate with the core dimer include three families of regulatory subunits B (the R2/B/PR55/B55, R3/B’’/PR72/PR130/PR59 and R5/B’/B56 families), the 48 kDa variable regulatory subunit, viral proteins, and cell signaling molecules. Interacts with ENSA (when phosphorylated at ‘Ser-67’) and ARPP19 (when phosphorylated at ‘Ser-62’), leading to inhibit PP2A activity. Interacts with IER5.

Subcellular location. Cytoplasm.

Similarity. Belongs to the phosphatase 2A regulatory subunit B family.

RefSeq proteins (2): NP_001278239, NP_060931* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000009	PP2A_PR55	Family
IPR001680	WD40_rpt	Repeat
IPR015943	WD40/YVTN_repeat-like_dom_sf	Homologous_superfamily
IPR018067	PP2A_PR55_CS	Conserved_site
IPR036322	WD40_repeat_dom_sf	Homologous_superfamily

UniProt features (16 total): repeat 7, sequence conflict 4, modified residue 3, chain 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q66LE6-F1	91.81	0.78

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (3): 308, 285, 305

Function

Pathways and Gene Ontology

Reactome pathways

5 pathways

ID	Pathway
R-HSA-2465910	MASTL Facilitates Mitotic Progression
R-HSA-1640170	Cell Cycle
R-HSA-68875	Mitotic Prophase
R-HSA-68886	M Phase
R-HSA-69278	Cell Cycle, Mitotic

MSigDB gene sets: 120 (showing top): BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_DN, GOBP_CELL_CYCLE_PHASE_TRANSITION, KEGG_TIGHT_JUNCTION, GOBP_ORGANELLE_FISSION, GOBP_REGULATION_OF_CHROMOSOME_SEGREGATION, GOBP_EXIT_FROM_MITOSIS, GOBP_REGULATION_OF_CELL_CYCLE, GOBP_MITOTIC_NUCLEAR_DIVISION, GOBP_MITOTIC_CELL_CYCLE, LASTOWSKA_NEUROBLASTOMA_COPY_NUMBER_DN, GOBP_REGULATION_OF_CELL_CYCLE_PROCESS, GOBP_CELL_DIVISION, GOBP_CELL_CYCLE_PROCESS, GOCC_PROTEIN_PHOSPHATASE_TYPE_2A_COMPLEX, GEORGES_TARGETS_OF_MIR192_AND_MIR215

GO Biological Process (4): mitotic cell cycle (GO:0000278), exit from mitosis (GO:0010458), cell division (GO:0051301), regulation of chromosome segregation (GO:0051983)

GO Molecular Function (3): protein phosphatase regulator activity (GO:0019888), enzyme-substrate adaptor activity (GO:0140767), protein binding (GO:0005515)

GO Cellular Component (3): protein phosphatase type 2A complex (GO:0000159), cytosol (GO:0005829), cytoplasm (GO:0005737)

Reactome top-level categories

Rollup of top-4 pathways:

Category	Pathways
Mitotic Prophase	1
M Phase	1
Cell Cycle, Mitotic	1
Cell Cycle	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
mitotic nuclear division	2
cellular anatomical structure	2
cell cycle	1
mitotic cell cycle phase transition	1
cellular process	1
chromosome segregation	1
regulation of cell cycle process	1
phosphoprotein phosphatase activity	1
phosphatase regulator activity	1
protein phosphatase binding	1
protein-macromolecule adaptor activity	1
binding	1
protein serine/threonine phosphatase complex	1
cytoplasm	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

1698 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PPP2R2D	ENSA	O43768	972
PPP2R2D	ARPP19	P56211	970
PPP2R2D	MASTL	Q96GX5	959
PPP2R2D	PPP2R1A	P30153	880
PPP2R2D	PPP2R5A	Q15172	863
PPP2R2D	PPP2CA	P05323	855
PPP2R2D	PPP2R2A	P50409	791
PPP2R2D	PPP2R3C	Q969Q6	775
PPP2R2D	CDK1	P06493	744
PPP2R2D	PPP2R5D	Q14738	744
PPP2R2D	PPP2R5E	Q16537	739
PPP2R2D	PPP2R5B	Q15173	736
PPP2R2D	PPP2R3A	Q06190	732
PPP2R2D	PPP2R5C	Q13362	723
PPP2R2D	PPP2R3B	Q9Y5P8	719

IntAct

182 interactions, top by confidence:

A	B	Type	Score
PPME1	PPP2R1A	psi-mi:“MI:0914”(association)	0.950
PPP2R1A	STRN	psi-mi:“MI:0914”(association)	0.880
PPP2R1A	STRN	psi-mi:“MI:2364”(proximity)	0.880
PABIR1	PPP2R1A	psi-mi:“MI:0914”(association)	0.880
PPME1	PPP2CA	psi-mi:“MI:0914”(association)	0.880
PPP2CA	STRN	psi-mi:“MI:0914”(association)	0.840
PPP2CB	STRN	psi-mi:“MI:0914”(association)	0.790
CDCA4	PPP2R1A	psi-mi:“MI:0914”(association)	0.790
SARNP	DDX39A	psi-mi:“MI:0914”(association)	0.740
PPP2R2D	YEATS4	psi-mi:“MI:0914”(association)	0.730
PPP2CB	CEP43	psi-mi:“MI:0914”(association)	0.730
SERTAD4	PPP2R1A	psi-mi:“MI:0914”(association)	0.730
RBM7	PPP2R1A	psi-mi:“MI:0914”(association)	0.730
CFTR	ESYT2	psi-mi:“MI:0914”(association)	0.710
FAM9C	NDC80	psi-mi:“MI:0914”(association)	0.670
ZNF414	AHCYL1	psi-mi:“MI:0914”(association)	0.640
SARNP	ZC3H11A	psi-mi:“MI:0914”(association)	0.610

BioGRID (345): DAPK1 (Affinity Capture-Western), PPP2CA (Affinity Capture-Western), PPP2R1A (Affinity Capture-Western), PPP2R5A (Affinity Capture-Western), PPP2R2D (Affinity Capture-Western), PPP2R2D (Affinity Capture-Western), DAPK1 (Biochemical Activity), PPP2R2D (Affinity Capture-MS), PPP2R2D (Affinity Capture-MS), PPP2R2D (Affinity Capture-MS), PPP2R2D (Affinity Capture-MS), PPP2R2D (Affinity Capture-MS), PPP2R2D (Affinity Capture-MS), PPP2R2D (Affinity Capture-MS), PPP2R2D (Affinity Capture-MS)

ESM2 similar proteins: A1L3L9, A2X2K3, B0R0D7, B6VA23, O35142, O55029, P35606, P36876, P36877, P50410, P54614, P56932, P63150, P63151, P97888, Q00005, Q00006, Q0D2F4, Q0E2P1, Q29090, Q38821, Q39247, Q4R4I8, Q4R7Z4, Q4R8L3, Q5E9Q7, Q5R4A2, Q5R664, Q5Z8Z7, Q5ZIY5, Q66LE6, Q6AY57, Q6DIY3, Q6NY64, Q6P1F6, Q6QEF8, Q6ZWR4, Q7ZWU5, Q7ZX64, Q80W47

Diamond homologs: A1L3L9, A2X2K3, B6VA23, G5EDR3, P36872, P36876, P36877, P50410, P53031, P54614, P56932, P63150, P63151, P97888, Q00005, Q00006, Q00362, Q0D2F4, Q0E2P1, Q12702, Q29090, Q38821, Q39247, Q4R7Z4, Q4R8L3, Q54Q99, Q5E9Q7, Q5R4A2, Q5Z8Z7, Q5ZIY5, Q66LE6, Q6DIY3, Q6NY64, Q6P1F6, Q6ZWR4, Q7ZX64, Q8BG02, Q925E7, Q95LP0, Q9Y2T4

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
ARPP19	“down-regulates activity”	PPP2R2D	binding
ENSA	“down-regulates activity”	PPP2R2D	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 198 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Co-inhibition by CTLA4	5	21.4×	4e-04
Disassembly of the destruction complex and recruitment of AXIN to the membrane	6	17.7×	2e-04
Co-stimulation by CD28	5	15.7×	6e-04
Cyclin A/B1/B2 associated events during G2/M transition	6	15.3×	4e-04
RAF activation	5	13.9×	9e-04
Cyclin D associated events in G1	6	11.6×	6e-04
RHO GTPase Effectors	10	5.6×	6e-04
Intracellular signaling by second messengers	7	5.3×	9e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

5 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	2
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
979909	GRCh37/hg19 10q26.2-26.3(chr10:129031265-135427143)x1	Pathogenic

SpliceAI

1055 predictions. Top by Δscore:

Variant	Effect	Δscore
10:131945458:GT:G	donor_gain	1.0000
10:131947526:TCAG:T	acceptor_loss	1.0000
10:131947527:CAGT:C	acceptor_loss	1.0000
10:131947528:A:AG	acceptor_gain	1.0000
10:131947528:AGTT:A	acceptor_loss	1.0000
10:131947529:G:GA	acceptor_gain	1.0000
10:131947529:GTT:G	acceptor_gain	1.0000
10:131947701:TCCAC:T	donor_gain	1.0000
10:131940196:GGT:G	donor_loss	0.9900
10:131940197:G:GG	donor_gain	0.9900
10:131940197:GT:G	donor_loss	0.9900
10:131940198:T:G	donor_loss	0.9900
10:131944882:G:GT	donor_gain	0.9900
10:131945287:A:AG	acceptor_gain	0.9900
10:131945460:G:GG	donor_gain	0.9900
10:131947529:GT:G	acceptor_gain	0.9900
10:131947529:GTTT:G	acceptor_gain	0.9900
10:131947529:GTTTT:G	acceptor_gain	0.9900
10:131955682:A:AG	acceptor_gain	0.9900
10:131955683:G:GG	acceptor_gain	0.9900
10:131955683:GC:G	acceptor_gain	0.9900
10:131945457:AGT:A	donor_gain	0.9800
10:131945458:GTG:G	donor_gain	0.9800
10:131945459:TGT:T	donor_gain	0.9800
10:131947527:CAG:C	acceptor_gain	0.9800
10:131947702:CCACG:C	donor_gain	0.9800
10:131947762:GTT:G	donor_gain	0.9800
10:131947763:TTT:T	donor_gain	0.9800
10:131947788:ATAGG:A	donor_loss	0.9800
10:131947789:TAG:T	donor_loss	0.9800

AlphaMissense

3062 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
10:131901303:G:A	G25R	1.000
10:131901303:G:C	G25R	1.000
10:131934503:T:A	L49H	1.000
10:131934503:T:C	L49P	1.000
10:131934505:G:C	A50P	1.000
10:131934506:C:A	A50E	1.000
10:131934511:G:A	G52R	1.000
10:131934511:G:C	G52R	1.000
10:131934512:G:A	G52E	1.000
10:131934512:G:T	G52V	1.000
10:131934514:G:C	D53H	1.000
10:131934523:G:C	G56R	1.000
10:131934524:G:A	G56D	1.000
10:131934524:G:T	G56V	1.000
10:131934530:T:A	V58D	1.000
10:131934538:T:C	F61L	1.000
10:131934539:T:C	F61S	1.000
10:131934540:T:A	F61L	1.000
10:131934540:T:G	F61L	1.000
10:131940085:A:C	S85R	1.000
10:131940087:T:A	S85R	1.000
10:131940087:T:G	S85R	1.000
10:131940100:T:C	F90L	1.000
10:131940101:T:C	F90S	1.000
10:131940101:T:G	F90C	1.000
10:131940102:T:A	F90L	1.000
10:131940102:T:G	F90L	1.000
10:131940103:G:C	D91H	1.000
10:131940110:T:C	L93S	1.000
10:131940110:T:G	L93W	1.000

dbSNP variants (sampled 300 via entrez): RS1000028134 (10:131933980 T>C,G), RS1000029226 (10:131946827 C>G), RS1000105926 (10:131960942 T>C), RS1000172600 (10:131910187 G>A,T), RS1000179267 (10:131949216 C>T), RS1000184491 (10:131913175 G>A), RS1000193384 (10:131971437 G>A), RS1000237864 (10:131910523 T>G), RS1000276249 (10:131929293 C>T), RS1000288424 (10:131915282 C>G), RS1000392460 (10:131924197 G>A), RS1000399391 (10:131956485 C>A,T), RS1000494090 (10:131967253 T>C), RS1000524059 (10:131900605 G>A), RS1000667991 (10:131944198 G>C)

Disease associations

OMIM: gene MIM:613992 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

8 associations (top):

Study	Trait	p-value
GCST004792_5	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals	9.000000e-06
GCST005316_354	Intelligence (MTAG)	4.000000e-09
GCST005790_20	Rosacea symptom severity	9.000000e-06
GCST006624_44	Systolic blood pressure	7.000000e-14
GCST007267_15	Systolic blood pressure	3.000000e-12
GCST007576_149	Chronotype	2.000000e-08
GCST009391_865	Metabolite levels	4.000000e-06
GCST009524_256	Household income (MTAG)	3.000000e-11

EFO canonical traits (6, from GWAS)

EFO ID	Trait name
EFO:0004337	intelligence
EFO:0009180	rosacea severity measurement
EFO:0006335	systolic blood pressure
EFO:0008328	chronotype measurement
EFO:0010534	suberic acid measurement
EFO:0009695	household income

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

32 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Copper	increases expression, affects binding	2
Tobacco Smoke Pollution	increases expression	2
Valproic Acid	increases methylation, increases expression	2
triphenyl phosphate	affects expression	1
mono-(2-ethylhexyl)phthalate	decreases expression	1
sodium arsenite	increases abundance, decreases expression	1
N,N,N’,N’-tetrakis(2-pyridylmethyl)ethylenediamine	decreases expression	1
CGP 52608	affects binding, increases reaction	1
entinostat	affects cotreatment, decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
abrine	increases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
bisphenol S	decreases methylation	1
NSC 689534	affects binding, increases expression	1
Resveratrol	affects cotreatment, increases expression	1
Vorinostat	decreases expression	1
Air Pollutants	affects expression, increases abundance	1
Arsenic	decreases expression, increases abundance	1
Benzo(a)pyrene	increases methylation	1
Chelating Agents	affects binding, increases expression	1
Methyl Methanesulfonate	increases expression	1
Ozone	affects expression, increases abundance	1
Plant Extracts	affects cotreatment, increases expression	1
Quercetin	increases expression	1
Thiram	increases expression	1
Tretinoin	decreases expression	1
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	decreases expression	1
Aflatoxin B1	increases methylation	1
Sodium Selenite	increases expression	1
Antirheumatic Agents	increases expression	1

Cellosaurus cell lines

3 cell lines: 3 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_TF98	HAP1 PPP2R2D (-) 1	Cancer cell line	Male
CVCL_TF99	HAP1 PPP2R2D (-) 2	Cancer cell line	Male
CVCL_TG00	HAP1 PPP2R2D (-) 3	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.